Evidence map›Paper›PMID 42558535›Full record

ArticleFrontiers in immunology2026

Bibliometric and visualization analysis of arginine deiminase research from 2006 to 2025: trends, collaboration networks and emerging frontiers.

Songtao Jiang, Lebin Gan, Qiang Wang, Guozheng Cao, Zhuang Zhang, Feifei Jin, Jing Zhou, Panpan Chang, Tianbing Wang, Jingjing Ye

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Songtao Jiang *Trauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Lebin Gan *Trauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Qiang WangTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Guozheng CaoTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Zhuang ZhangTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Feifei JinTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Jing ZhouTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Panpan ChangTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Tianbing WangTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.
Jingjing YeTrauma Treatment Center, Peking University People's Hospital; Key Laboratory of Trauma Treatment and Neural Regeneration (Peking University) Ministry of Education; National Center for Trauma Medicine, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Peptidylarginine Deiminase/Protein Arginine Deiminase (PAD/PADI) are a family of enzymes that catalyze protein citrullination, converting arginine residues to citrulline residues in a calcium-dependent manner. The net loss of positive charge of protein citrullination results in change of conformation, including probable formation of neoepitopes, and interactions with substances like DNA, which contributes to physiologic and pathophysiologic processes such as regulation of gene expression, Neutrophil Extracellular Traps (NETs), Rheumatoid Arthritis (RA), and Multiple Sclerosis (MS). To date, studies of PADs pan- and selective inhibitors have been deepening. This bibliometric analysis tries to give a comprehensive conclusion on research progress of peptidylarginine deiminases (PAD) and PAD inhibitors. Methods: In this study, we aggregated publications using a dual-database strategy (Web of Science and PubMed) from January 1, 2006, to December 5, 2025, with a specific focus on the arginine deiminase research. Utilizing bibliometric methods, the data underwent processing to facilitate visual analysis of various aspects, including countries, institutions, authors, co-citations, keywords, references, gene characteristics, and diseases. Results: Over the past two decades, the number of publications on the PAD family has increased continuously, with the United States contributing the largest number of publications. The University of Massachusetts emerged as the most prolific institution with 73 publications, while Paul R. Thompson was identified as the leading author in this field. Frontiers in Immunology published the highest number of PAD-related articles. High-frequency keywords included "rheumatoid arthritis", "neutrophil extracellular traps", "citrullination", "PADI", and "arginine deiminase". Recent trends, identified through strong citation bursts from 2022 to 2025, include neutrophil extracellular traps, PADI4, and the tumor microenvironment. The high-frequency genes in the PADs field include PADI4, PADI2, TP53, and MPO. Additionally, pathways such as Lipid and atherosclerosis and viral infection-related pathways are significantly enriched in this research domain. Conclusions: The research maps the evolving landscape of PAD research over the past two decades. However, cooperation between institutions and countries remains limited, although trends indicate increasing cooperation. This study identifies major research hotspots and evolving trends within the PAD field, helping to guide future research directions and providing an objective, data-driven reference for tracking new frontiers in the field, rather than drawing biological conclusions.

Indexed as

BibliometricsProtein-Arginine DeiminasesAnimalsArthritis, RheumatoidCitrullinationExtracellular TrapsHumansHydrolasesarginine deiminaseHydrolasesProtein-Arginine Deiminasesautoimmune and immune-related diseasesbibliometric analysiscitrullinationPADsvisualization analysis

Identifiers

PMID42558535
PMCPMC13437694

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.